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339Abstracts
vious simulation models have shown the Rx-to-OTC switch of
loratadine to be cost-effective. The purpose of this research is to
empirically assess the overall impact of the Rx-to-OTC switch
of loratadine as well as the speciﬁc impact of different pharmacy
beneﬁt structures on prescription drug utilization and cost in a
variety of plan sponsors. METHODS: Data from a national
pharmacy beneﬁt management organization covering 27 million
lives throughout the US were used. The analysis included a com-
parison of the difference in prescription utilization and cost for
the 12-months after a change in prescription beneﬁts for second-
generation antihistamines (SGA) due to OTC loratadine com-
pared to 12-months before for plan sponsors that instituted no
change, moved SGA to the 3rd-tier and restricted SGA beneﬁts
through prior authorization requirement. Change in utilization
and cost of medications for allergic rhinitis (AR), asthma, respi-
ratory infections and all classes combined was examined. Mul-
tivariate regression analysis was used to control for differences
across study groups. RESULTS: There was a substantial decrease
in utilization and cost of all prescription drugs and combinations
of drug classes. AR patients facing restricted prescription bene-
ﬁts for SGA did not appear to increase utilization of other AR
medications or other medications used to treat comorbid condi-
tions such as asthma, sinusitis and otitis media. CONCLU-
SIONS: Utilization and cost decreased substantially for all types
of medications and all pharmacy beneﬁt structures. Future
studies need to examine the impact of the Rx-to-OTC switch of
loratadine and resultant prescription beneﬁt policies on medical
utilization and OTC antihistamine utilization.
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OBJECTIVE: To examine patient perceptions regarding medica-
tion efﬁcacy, safety and cost of using over-the-counter (OTC)
Claritin and its impact on work related productivity.
METHODS: A web-based survey was administered to employ-
ees of a large University via a voluntary-based e-mail list. Survey
items included the choice of medication used by individuals prior
to and following the availability of OTC Claritin, perceptions of
efﬁcacy, symptom control, cost and safety of OTC Claritin as
well perceptions of work related productivity. Bivariate compar-
isons using chi square analysis were used to describe the study
results. RESULTS: Sample consisted of 221 respondents of which
19% were either taking a prescription medication or nasal spray,
other OTC medications, both a prescription and OTC medica-
tion, allergy shots, herbal medications or who were not treating
their allergies prior to the availability of OTC Claritin switched
to OTC Claritin. Older individuals were less likely to switch to
OTC Claritin. Half the individuals who switched from prescrip-
tion medication to OTC Claritin reported having better control
of their allergic rhinitis symptoms (p < 0.05). In total, 88% of
these individuals reported no difference in side effects between
their prescription medication and OTC Claritin, while 82%
reported that OTC Claritin was more expensive than their prior
prescription medication (p < 0.05). However, only 28% of these
individuals reported their allergy symptoms did not interfere at
all with their work while taking OTC Claritin, while 38%
reported that they were only between 60–80% as productive at
work when taking OTC Claritin. CONCLUSIONS: Preliminary
results suggest that the adoption of OTC Claritin may not be as
widespread as anticipated. While patients’ report equal or better
symptom control with OTC Claritin, self reports of work related
productivity do not appear to corroborate these ﬁndings. Further
research is needed to examine the indirect impact of OTC Clar-
itin on presenteism and absenteeism.
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OBJECTIVES: Patients’ willingness to pay (WTP) for intranasal
corticosteroid (INS) products was evaluated. METHODS: One
hundred twenty patients with allergic rhinitis were recruited
from four US allergy/immunology clinics. Participants chose
between hypothetical INSs differing in degree across six attrib-
utes (smell, taste, aftertaste, throat rundown, nose runout, and
feel of spray) and monthly co-pays ($15, $30, and $50). Attrib-
utes were deﬁned in three levels (strong, weak, and none).
Strength of preference was measured as marginal WTP to avoid
higher-degree levels. RESULTS: Patients were willing to pay $11
(95% conﬁdence interval [CI]: $9 to $13) per month to avoid
strong smell over no smell, $12 (95% CI: $10 to $14) to avoid
strong taste over no taste, $20 (95% CI: $18 to $22) to 
avoid strong aftertaste over no aftertaste, $10 (95% CI: $9 to
$12) to avoid excess throat rundown over no throat rundown,
$11 (95% CI: $9 to $13) to avoid excess nose runout over no
nose runout, and $6 (95% CI: $4 to $8) per month to avoid dry
spray over moist spray. When moderate to low levels were com-
pared, aftertaste, throat rundown, and nose runout were still
associated with a signiﬁcant WTP. Income level was not associ-
ated with changes in WTP except for throat rundown. Patients
with an income >$80,000 were willing to pay more to avoid
excess throat rundown than those with an income <$0,000.
CONCLUSIONS: Patients are willing to pay for an INS with
favorable sensory attributes.
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OBJECTIVE: In September, 2004, rofecoxib was withdrawn
from the market due to cardiovascular safety concerns, and con-
cerns have been raised about the cardiovascular safety of other
Cox-2s. This study identiﬁes the characteristics of Cox-2 users
in the six months preceding rofecoxib withdrawal and tracks the
NSAID utilization of this cohort by cardiovascular risk and other
characteristics. METHODS: Pharmacy claims from a large,
private pharmacy beneﬁt management ﬁrm were analyzed. Indi-
viduals with a claim for any Cox-2 inhibitor in the 180 days
prior to rofecoxib withdrawal were identiﬁed, and their cardio-
vascular risk assessed on a surrogate measure based on pharmacy
claims. Subsequent NSAID utilization of this cohort was tracked
through December, 2004 and through mid-2005. RESULTS:
Over 130,000 Cox-2 users were identiﬁed in the six months prior
to rofecoxib withdrawal. Thirty-four percent were male, 31%
age 65 or older, and 31% had a pharmaceutical marker sug-
gesting cardiovascular risk. In the three months following rofe-
coxib withdrawal, 50% of Cox-2 users had a claim for an
NSAID (Cox-2 or non-selective NSAID), and individuals with
CV risk were more likely than those at lower risk to have an
NSAID claim (57% vs. 47%, p < 0.0001). Of those with an
